^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MIT-001

    i
    Other names: MIT-001, MIT 001, LC28-0126, LC280126, LC-280126, NX-7, NecroX-7, LC 280126, MIT001, NX7, NX 7
    Associations

    News

    Trials
    Company:
    LG Chem, MitoImmune Therap
    Drug class:
    Oxygen radical scavenger, Reactive oxygen species inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Inhibition of SLC25A10 promotes cellular senescence and impedes hepatocellular carcinoma progression. (PubMed, Transl Cancer Res)
    SLC25A10 promotes HCC progression by suppressing cellular senescence. Pharmacological or genetic inhibition of SLC25A10 triggers tumor suppression through HMGB1-mediated SASP signaling, positioning SLC25A10 as a promising therapeutic target for HCC intervention.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • HMGB1 (High Mobility Group Box 1) • PCNA (Proliferating cell nuclear antigen)
    |
    MIT-001
    6ms
    Suppression of MRPL23 induces cellular senescence in hepatocellular carcinoma by targeting HMGB1. (PubMed, Discov Oncol)
    Finally, we confirmed that MRPL23 regulated cellular senescence by targeting HMGB1 using the inhibitor NecroX-7. These findings laid the foundation for developing potential therapies for HCC by inhibiting MRPL23 or inducing senescence.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • RPL23 (Ribosomal Protein L23)
    |
    MIT-001
    9ms
    MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, MitoImmune Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    MIT-001
    over1year
    Capella: Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, MitoImmune Therapeutics | Recruiting --> Active, not recruiting | Phase classification: P2a --> P2 | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Jun 2024
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    MIT-001
    over3years
    Capella: Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT (clinicaltrials.gov)
    P2a, N=75, Recruiting, MitoImmune Therapeutics
    New P2a trial
    |
    CD34 (CD34 molecule)
    |
    MIT-001